The CK2-ERK SPS Phosphorylation Axis as an Age-Regulated Switch for Nuclear ERK Retention and Senescence

Dr. Julian Herrera (MD)· Mar 12, 2026

transmission electron micrograph of aged fibroblast nucleus, phosphorylated ERK protein clusters at nuclear pore complexes, monochrome amber stain, high magnification detail

Hypothesis

We propose that chronological aging hyperactivates the CK2-mediated phosphorylation of ERK's SPS motif (Ser-244/Pro-245/Ser-246) [via an age-dependent loss of p53-driven negative feedback], leading to excessive nuclear importin7 binding, sustained nuclear ERK retention, and senescence entry. In contrast, in induced senescence models, this feedback remains partially intact, allowing transient nuclear ERK and potential senescence bypass.

Background

ERK1/2 nuclear-cytoplasmic shuttling presents a paradox: sustained nuclear ERK promotes senescence via SASP and cell cycle arrest, yet systemic reduction of RAS/ERK signaling extends lifespan and may permit senescence bypass in model organisms. The import machinery is well-defined: dual-phosphorylated ERK requires CK2 phosphorylation of its SPS motif for importin7 binding and nuclear translocation Chuderland et al., 2008; reviewed here. However, how this machinery's efficiency changes with age versus acute senescence induction is unknown [, 2026], and how ERK dynamics interact with core senescence pathways like p53/p16 in vivo remains unresolved.

Novel Mechanistic Reasoning

Age-dependent CK2 dysregulation: CK2 activity often increases with age due to oxidative stress and epigenetic changes, potentially leading to constitutive hyperphosphorylation of ERK's SPS motif. This would enhance importin7 binding independently of upstream MEK activity, creating a "locked" nuclear ERK state that drives senescence even with moderate ERK activation.
p53-CK2 negative feedback loop: We hypothesize that nuclear ERK activates p53 as shown in some contexts, which then transcriptionally upregulates a CK2 inhibitor (e.g., protein kinase CK2 inhibitor alpha, CSNK2A1) or a phosphatase targeting the SPS motif. This creates a negative feedback loop limiting nuclear ERK retention. In aging, p53 function declines or its targets are epigenetically silenced, breaking the feedback and allowing runaway CK2-ERK nuclear signaling.
Tissue-specificity via p16/RB: In epithelial tissues, p16/RB may compete with importin7 for ERK binding or alter CK2 localization, explaining tissue-specific aging phenotypes. Senescent fibroblasts show persistent ERK-driven MMP expression [Frontiers, 2025], but hepatocytes or neurons might differentially regulate this axis.
Senescence bypass implications: In induced senescence (e.g., oncogene activation), the feedback loop is initially intact, allowing transient nuclear ERK followed by cytoplasmic relocalization, enabling possible cell cycle re-entry upon stress removal Cellular senescence: Neither irreversible nor uniform, 2024. Aging, however, permanently disables this kinetic plasticity.

Testable Predictions

Kinetics assay: Measure CK2 activity and ERK SPS phosphorylation in primary fibroblasts from young vs. old donors, and in young cells undergoing oncogene-induced senescence. Prediction: old cells show higher basal CK2 activity and SPS phosphorylation, with slower nuclear export upon MEK inhibition.
Feedback loop test: In p53-knockout young cells, predict increased nuclear ERK retention and accelerated senescence. Conversely, overexpress CK2 inhibitors in old cells to restore nuclear export dynamics.
Tissue comparison: Compare ERK shuttling kinetics in aged dermal fibroblasts vs. aged hepatocytes or astrocytes. Prediction: fibroblasts show stronger CK2-ERK dysregulation, correlating with SASP markers.
Therapeutic window: Use CK2 inhibitors (e.g., CX-4945) or SPS-mimetic peptides to decouple ERK activation from nuclear import in aged cells. Prediction: they reduce nuclear ERK, suppress SASP, and allow cell cycle re-entry without increasing oncogenic transformation markers.

Implications

This hypothesis reframes the ERK senescence paradox as a kinetic failure of negative feedback rather than absolute signaling levels. It identifies the CK2-SPS axis as a druggable node that could potentially reverse age-associated senescence without broadly inhibiting beneficial cytoplasmic ERK functions. If confirmed, it suggests that senolytic strategies should target the import machinery's regulation, not just ERK activity itself.

Hypothesis

Background

Novel Mechanistic Reasoning

Age-dependent CK2 dysregulation: CK2 activity often increases with age due to oxidative stress and epigenetic changes, potentially leading to constitutive hyperphosphorylation of ERK's SPS motif. This would enhance importin7 binding independently of upstream MEK activity, creating a "locked" nuclear ERK state that drives senescence even with moderate ERK activation.

p53-CK2 negative feedback loop: We hypothesize that nuclear ERK activates p53 as shown in some contexts, which then transcriptionally upregulates a CK2 inhibitor (e.g., protein kinase CK2 inhibitor alpha, CSNK2A1) or a phosphatase targeting the SPS motif. This creates a negative feedback loop limiting nuclear ERK retention. In aging, p53 function declines or its targets are epigenetically silenced, breaking the feedback and allowing runaway CK2-ERK nuclear signaling.

Tissue-specificity via p16/RB: In epithelial tissues, p16/RB may compete with importin7 for ERK binding or alter CK2 localization, explaining tissue-specific aging phenotypes. Senescent fibroblasts show persistent ERK-driven MMP expression [Frontiers, 2025], but hepatocytes or neurons might differentially regulate this axis.

Senescence bypass implications: In induced senescence (e.g., oncogene activation), the feedback loop is initially intact, allowing transient nuclear ERK followed by cytoplasmic relocalization, enabling possible cell cycle re-entry upon stress removal Cellular senescence: Neither irreversible nor uniform, 2024. Aging, however, permanently disables this kinetic plasticity.

Testable Predictions

Kinetics assay: Measure CK2 activity and ERK SPS phosphorylation in primary fibroblasts from young vs. old donors, and in young cells undergoing oncogene-induced senescence. Prediction: old cells show higher basal CK2 activity and SPS phosphorylation, with slower nuclear export upon MEK inhibition.

Feedback loop test: In p53-knockout young cells, predict increased nuclear ERK retention and accelerated senescence. Conversely, overexpress CK2 inhibitors in old cells to restore nuclear export dynamics.

Tissue comparison: Compare ERK shuttling kinetics in aged dermal fibroblasts vs. aged hepatocytes or astrocytes. Prediction: fibroblasts show stronger CK2-ERK dysregulation, correlating with SASP markers.

Therapeutic window: Use CK2 inhibitors (e.g., CX-4945) or SPS-mimetic peptides to decouple ERK activation from nuclear import in aged cells. Prediction: they reduce nuclear ERK, suppress SASP, and allow cell cycle re-entry without increasing oncogenic transformation markers.

Implications